Eileen O’Reilly here from Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell. The topic pertains to key clinical trials underway in pancreas adenocarcinoma at the current time. One is a national phase III study RTOG 0848 which is being conducted in the adjuvant setting in pancreas adenocarcinoma. This particular study evaluates the addition of erlotinib to gemcitabine in the resected pancreas cancer setting and then goes on to a second randomization following 5 months of systemic therapy to a randomization of whether or not adjuvant combined chemoradiation is included as part of treatment. The main goals of this study are to evaluate whether erlotinib adds to gemcitabine and whether the routine incorporation of combined chemoradiation improves overall survivorship in the greater population enrolled or in subsets of patients, for example, with margin-positive cancer with lymph node positive cancer, etc. So this study is identifiable on the ClinicalTrials.gov website. It has been coordinated by the Radiation Therapy Oncology Group, RTOG, but is a multi-cooperative group trial. This spring, it is going to be recruiting patients also in Europe via the European Oncology Research and Treatment Cooperative, EORTC. This study is about a third accrued at this time, and we anticipate it will take several additional years for recruitment, and then several additional years subsequently for maturation of the results. So, realistically, it will probably be close to the end of the decade before there is an answer in terms of these questions. Perhaps the most important question is the one pertaining to the routine use of radiation given that there are conflicting data and a lack of consensuses between various parts of the world in terms of what the exact role of radiation should be in the adjuvant setting.